Literature DB >> 11929749

The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex.

Alexander B Maurer1, Christian Wichmann, Alexandra Gross, Hana Kunkel, Thorsten Heinzel, Martin Ruthardt, Bernd Groner, Manuel Grez.   

Abstract

The transcription factor Stat5 mediates the cellular response to activation of multiple cytokine receptors involved in the regulation of proliferation and differentiation of hematopoietic cells. Recently, the human Stat5 gene was found to be translocated to the RARalpha gene in a patient with acute promyelocytic leukemia indicating that Stat5 might also play a role in cellular transformation. We investigated the mechanism by which Stat5 might exert this function and studied the biochemical and cellular functions of fusion proteins comprising Stat5 and RARalpha. The expression of Stat5-RARalpha causes the transcriptional repression of gene transcription, a process that requires the coiled-coil domain of Stat5 (amino acid positions 133-333). Oligomerization of this domain in the Stat5-RARalpha fusion protein leads to stable binding of the corepressor SMRT independent of all-trans retinoic acid (ATRA) stimulation and is accompanied by an impaired response to differentiation signals in hematopoietic cells. This inhibitory effect on myeloid differentiation cannot be overcome by simultaneous coexpression of RARalpha. We conclude that Stat5 is capable of interacting with a corepressor complex that alters the pattern of corepressor binding to RARalpha and its dissociation in response to ATRA stimulation, leading to enhanced repressor activity and a block of hematopoietic differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929749     DOI: 10.1182/blood.v99.8.2647

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.

Authors:  Anne Rascle; James A Johnston; Bruno Amati
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 2.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 3.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

4.  Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.

Authors:  Kshama Gupta; Inna Kuznetsova; Olga Klimenkova; Maksim Klimiankou; Johann Meyer; Malcolm A S Moore; Cornelia Zeidler; Karl Welte; Julia Skokowa
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

Review 5.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

6.  The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2.

Authors:  Oliver H Krämer; Ping Zhu; Heather P Ostendorff; Martin Golebiewski; Jens Tiefenbach; Marvin A Peters; Boris Brill; Bernd Groner; Ingolf Bach; Thorsten Heinzel; Martin Göttlicher
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

7.  Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.

Authors:  Cristina E Tognon; Cameron D Mackereth; Aruna M Somasiri; Lawrence P McIntosh; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 8.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 9.  Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.

Authors:  Zhiyong Liao; Jacqueline Lutz; Marja T Nevalainen
Journal:  Int J Biochem Cell Biol       Date:  2009-11-13       Impact factor: 5.085

Review 10.  Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Authors:  Xiang Zhang; Jiewen Sun; Wenjuan Yu; Jie Jin
Journal:  Biomark Res       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.